Cisapride

Summary

Cisapride (CHEMBL1729) is an approved small molecule (ATC A03FA02) targeting HTR7, KCNH2, and HTR4; indicated across 1 condition.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A03FA02
• Targets: 3 (HTR7, KCNH2, HTR4)
• Indications: 1 condition
• Clinical trials: 4
• Chemistry: 465.9 Da · C23H29ClFN3O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1729
Name	Cisapride
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	2769
ATC	A03FA02
Molecular formula	C23H29ClFN3O4
Molecular weight	465.9
InChIKey	DCSUBABJRXZOMT-UHFFFAOYSA-N

SMILES: COC1CN(CCC1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F

IUPAC name: 4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl]-2-methoxybenzamide

Also known as: Cisaprida, Cisapride, R-51,619, R-51619, cisapride, rel-Cisapride, CISAPRIDE, SID144204250, rel-cisapride, SID170465200

Parent form; salt/anhydrous children: CHEMBL1200788

Patent coverage: 4,036 distinct patent families (14,365 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
HTR7	5-HT7 receptor	Full agonist	5.8	0.8%	P34969
KCNH2	Kv11.1		7.4	0.3%	Q12809
HTR4	5-HT4 receptor	Partial agonist	7.4	0%	Q13639

Broader ChEMBL bioactivity targets: 47 (assay-derived). Sample: 5-hydroxytryptamine receptor 2B, Alpha-2A adrenergic receptor, 5-hydroxytryptamine receptor 4, 5-hydroxytryptamine receptor 3A, Adrenergic receptor alpha-1, Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor, Sodium channel protein type 5 subunit alpha, D(1A) dopamine receptor, Thromboxane A2 receptor.

Bioactivity

ChEMBL activities: 133 potent at pChembl ≥ 5 of 141 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HTR4	9.44	IC50	0.36	nM	CHEMBL_ACT_17727638
HTR2A	8.96	Ki	1.1	nM	CHEMBL_ACT_7686596
HTR2A	8.41	IC50	3.86	nM	CHEMBL_ACT_7686595
P08909	8.21	Ki	6.1	nM	CHEMBL_ACT_1275385
HTR2A	8.21	IC50	6.1	nM	CHEMBL_ACT_1457760
HTR2A	8.21	IC50	6.1	nM	CHEMBL_ACT_1676734
HTR2A	8.2	Ki	6.31	nM	CHEMBL_ACT_13375224
KCNH2	8.19	IC50	6.46	nM	CHEMBL_ACT_1429836
KCNH2	8.19	IC50	6.5	nM	CHEMBL_ACT_15257954
KCNH2	8.19	IC50	6.46	nM	CHEMBL_ACT_2645532
KCNH2	8.19	IC50	6.5	nM	CHEMBL_ACT_332177
KCNH2	8.17	IC50	6.7	nM	CHEMBL_ACT_2295034
KCNH2	8.17	IC50	6.7	nM	CHEMBL_ACT_2295145
KCNH2	8.17	IC50	6.76	nM	CHEMBL_ACT_5219048
Q75Z89	8.14	Ki	7.2	nM	CHEMBL_ACT_1044932
P15823	8.06	Ki	8.65	nM	CHEMBL_ACT_7684378
P08909	8.01	IC50	9.8	nM	CHEMBL_ACT_514383
KCNH2	8	IC50	10	nM	CHEMBL_ACT_2609303
KCNH2	7.96	IC50	10.92	nM	CHEMBL_ACT_26048469
KCNH2	7.94	IC50	11.38	nM	CHEMBL_ACT_26045099
KCNH2	7.92	IC50	12	nM	CHEMBL_ACT_18591411
O70528	7.84	Ki	14.3	nM	CHEMBL_ACT_1204393
KCNH2	7.82	IC50	15.04	nM	CHEMBL_ACT_25857390
P15823	7.8	IC50	16	nM	CHEMBL_ACT_7684377
O70528	7.77	Ki	17	nM	CHEMBL_ACT_1676725
HTR2A	7.71	AC50	19.7	nM	CHEMBL_ACT_25173723
O70528	7.7	Ki	20	nM	CHEMBL_ACT_14711040
O70528	7.7	Ki	20	nM	CHEMBL_ACT_18729433
KCNH2	7.55	IC50	28.1	nM	CHEMBL_ACT_25486889
HTR4	7.54	Ki	29	nM	CHEMBL_ACT_906541

Target pathways

Aggregated over 3 target gene(s): HTR7, KCNH2, HTR4.

Top Reactome pathways

15 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	2	HTR4, HTR7
Signaling by GPCR	2	HTR4, HTR7
Class A/1 (Rhodopsin-like receptors)	2	HTR4, HTR7
Amine ligand-binding receptors	2	HTR4, HTR7
GPCR downstream signalling	2	HTR4, HTR7
Serotonin receptors	2	HTR4, HTR7
G alpha (s) signalling events	2	HTR4, HTR7
GPCR ligand binding	2	HTR4, HTR7
Neuronal System	1	KCNH2
Potassium Channels	1	KCNH2
Voltage gated Potassium channels	1	KCNH2
Muscle contraction	1	KCNH2
Phase 3 - rapid repolarisation	1	KCNH2
Cardiac conduction	1	KCNH2
RHOBTB3 ATPase cycle	1	HTR7

Dominant GO biological processes

GO term	Targets
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	2
adenylate cyclase-activating serotonin receptor signaling pathway	2
chemical synaptic transmission	2
signal transduction	2
G protein-coupled receptor signaling pathway	2
G protein-coupled serotonin receptor signaling pathway	2
smooth muscle contraction	1
circadian rhythm	1
blood circulation	1
vasoconstriction	1
regulation of heart rate by hormone	1
potassium ion transport	1
regulation of membrane potential	1
positive regulation of DNA-templated transcription	1
potassium ion homeostasis	1

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4).

The 1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE4	4

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01281540	PHASE4	TERMINATED	An Efficacy and Safety Study of Cisapride in Patients With Chronic Gastroparesis After Failure of Other Treatment Options
NCT01281553	PHASE4	TERMINATED	A Study of Cisapride in Patients With Symptomatic Gastro-Oesophageal Reflux Disease
NCT01281566	PHASE4	TERMINATED	A Study of Cisapride in Premature Infants With Feeding Problems
NCT01286090	PHASE4	TERMINATED	An Efficacy and Safety Study of Cisapride for Improving Symptoms Associated With Gastroparesis in Patients With Diabetes Mellitus

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 4 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

673 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
CYPROHEPTADINE	ChEMBL + PubChem	Phase 4 (approved)	HTR4, HTR7, KCNH2
HALOPERIDOL	ChEMBL + PubChem	Phase 4 (approved)	HTR4, HTR7, KCNH2
IMIPRAMINE	ChEMBL + PubChem	Phase 4 (approved)	HTR4, HTR7, KCNH2
Dihydroergotamine	ChEMBL + PubChem	Phase 4 (approved)	HTR7, KCNH2
DONEPEZIL	ChEMBL + PubChem	Phase 4 (approved)	HTR4, KCNH2
PALIPERIDONE	ChEMBL + PubChem	Phase 4 (approved)	HTR7, KCNH2
PRUCALOPRIDE	ChEMBL + PubChem	Phase 4 (approved)	HTR4, KCNH2
TEGASEROD	ChEMBL + PubChem	Phase 4 (approved)	HTR4, HTR7
AMISULPRIDE	ChEMBL	Phase 4 (approved)	HTR7, KCNH2
AMOXAPINE	ChEMBL	Phase 4 (approved)	HTR7, KCNH2
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	HTR7, KCNH2
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	HTR7, KCNH2
AZELASTINE	ChEMBL	Phase 4 (approved)	HTR7, KCNH2
BUSPIRONE	ChEMBL	Phase 4 (approved)	HTR7, KCNH2
CARIPRAZINE	ChEMBL	Phase 4 (approved)	HTR7, KCNH2
CINACALCET	ChEMBL	Phase 4 (approved)	HTR7, KCNH2
CLOZAPINE	ChEMBL	Phase 4 (approved)	HTR7, KCNH2
DOXEPIN	ChEMBL	Phase 4 (approved)	HTR7, KCNH2
KETANSERIN	ChEMBL	Phase 4 (approved)	HTR7, KCNH2
KETOTIFEN	ChEMBL	Phase 4 (approved)	HTR7, KCNH2
LURASIDONE	ChEMBL	Phase 4 (approved)	HTR7, KCNH2
MIANSERIN	ChEMBL	Phase 4 (approved)	HTR7, KCNH2
NEFAZODONE	ChEMBL	Phase 4 (approved)	HTR7, KCNH2
PERPHENAZINE	ChEMBL	Phase 4 (approved)	HTR7, KCNH2
PITOLISANT	ChEMBL	Phase 4 (approved)	HTR7, KCNH2
PROMAZINE	ChEMBL	Phase 4 (approved)	HTR7, KCNH2
SALMETEROL	ChEMBL	Phase 4 (approved)	HTR7, KCNH2
SILODOSIN	ChEMBL	Phase 4 (approved)	HTR7, KCNH2
THIORIDAZINE	ChEMBL	Phase 4 (approved)	HTR7, KCNH2
THIOTHIXENE	ChEMBL	Phase 4 (approved)	HTR7, KCNH2
TROPISETRON	ChEMBL	Phase 4 (approved)	HTR4, KCNH2
VILAZODONE	ChEMBL	Phase 4 (approved)	HTR7, KCNH2
ZIPRASIDONE	ChEMBL	Phase 4 (approved)	HTR7, KCNH2
NALUZOTAN	ChEMBL	Phase 3	HTR7, KCNH2
SEROTONIN	ChEMBL	Phase 3	HTR4, HTR7
GSK163090	ChEMBL	Phase 2	HTR7, KCNH2
LITOXETINE	ChEMBL	Phase 2	HTR4, HTR7
MEBUFOTENIN	ChEMBL	Phase 2	HTR4, HTR7
METERGOLINE	ChEMBL	Phase 2	HTR7, KCNH2
PIZOTYLINE	ChEMBL	Phase 2	HTR7, KCNH2
PRX-03140	ChEMBL	Phase 2	HTR4, KCNH2
SPIPERONE	ChEMBL	Phase 2	HTR7, KCNH2
Alogliptin	PubChem	Approved	HTR7, KCNH2
Pyrazinamide	PubChem	Approved	HTR7, KCNH2
Tiotropium Bromide Monohydrate	PubChem	Approved	HTR7, KCNH2
AFATINIB	ChEMBL + PubChem	Phase 4 (approved)	KCNH2
BREXPIPRAZOLE	ChEMBL + PubChem	Phase 4 (approved)	HTR7
GENTIAN VIOLET	ChEMBL + PubChem	Phase 4 (approved)	KCNH2
LASMIDITAN	ChEMBL + PubChem	Phase 4 (approved)	HTR7
MAVORIXAFOR	ChEMBL + PubChem	Phase 4 (approved)	KCNH2
PIMAVANSERIN	ChEMBL + PubChem	Phase 4 (approved)	KCNH2
PRAMIPEXOLE	ChEMBL + PubChem	Phase 4 (approved)	HTR7
PROPOXYPHENE	ChEMBL + PubChem	Phase 4 (approved)	KCNH2
RELUGOLIX	ChEMBL + PubChem	Phase 4 (approved)	KCNH2
RIOCIGUAT	ChEMBL + PubChem	Phase 4 (approved)	KCNH2
VORAPAXAR	ChEMBL + PubChem	Phase 4 (approved)	KCNH2
ABEMACICLIB	ChEMBL	Phase 4 (approved)	KCNH2
ACENOCOUMAROL	ChEMBL	Phase 4 (approved)	KCNH2
ACETOPHENAZINE	ChEMBL	Phase 4 (approved)	KCNH2
ACLIDINIUM BROMIDE	ChEMBL	Phase 4 (approved)	KCNH2